Harmony Biosciences Holdings Inc’s recently made public that its Former Officer JEFFREY G DIERKS acquired Company’s shares for reported $0.35 million on May 19 ’25. In the deal valued at $35.56 per share,9,844 shares were bought.
Then, JEFFREY G DIERKS bought 2,292 shares, generating $80,427 in total proceeds.
Before that, JEFFREY G DIERKS bought 5,000 shares. Harmony Biosciences Holdings Inc shares valued at $175,955 were divested by the Former Officer at a price of $35.19 per share.
Deutsche Bank initiated its Harmony Biosciences Holdings Inc [HRMY] rating to a Buy in a research note published on February 11, 2025; the price target was $55. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. UBS started covering the stock on September 10, 2024. It rated HRMY as “a Buy”.
Price Performance Review of HRMY
On Monday, Harmony Biosciences Holdings Inc [NASDAQ:HRMY] saw its stock jump 2.40% to $35.91. Over the last five days, the stock has gained 0.73%. Harmony Biosciences Holdings Inc shares have risen nearly 4.36% since the year began. Nevertheless, the stocks have risen 20.91% over the past one year.
How much short interest is there in Harmony Biosciences Holdings Inc?
A steep rise in short interest was recorded in Harmony Biosciences Holdings Inc stocks on 2025-04-30, dropping by -0.24 million shares to a total of 3.25 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 3.49 million shares. There was a decline of -7.5%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 21, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $48 price target.
